PTC Therapeutics (PTCT) FY23 Revenue Guidance Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
January 9, 2023 9:15 AM EST-Â ~$710 million unaudited 2022 total revenue, representing an impressive over 30% year-over-year growth
-Â $940 million - $1.0 billion 2023 total revenue guidance
-Â Results from three registration-directed clinical trials expected in 2023
-Â One additional registration-directed clinical trial expected to initiate in 2023
SOUTH PLAINFIELD, N.J., Jan. 9, 2023 /PRNewswire/ --Â PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 41st Annual J.P. Morgan Healthcare... More
